Bibliographic Details
| Title: |
Baricitinib Treatment of Coronavirus Disease 2019 Is Associated With a Reduction in Secondary Infections. |
| Authors: |
Sweeney, Daniel A, Tuyishimire, Bonifride, Ahuja, Neera, Beigel, John H, Beresnev, Tatiana, Cantos, Valeria D, Castro, Jose G, Cohen, Stuart H, Cross, Kaitlyn, Dodd, Lori E, Erdmann, Nathan, Fung, Monica, Ghazaryan, Varduhi, George, Sarah L, Grimes, Kevin A, Hynes, Noreen A, Julian, Kathleen G, Kandiah, Sheetal, Kim, Hannah Jang, Levine, Corri B |
| Source: |
Open Forum Infectious Diseases; May2023, Vol. 10 Issue 5, p1-4, 4p |
| Abstract: |
We performed a secondary analysis of the National Institutes of Health-sponsored Adaptive COVID-19 Treatment Trial (ACTT-2) randomized controlled trial and found that baricitinib was associated with a 50% reduction in secondary infections after controlling for baseline and postrandomization patient characteristics. This finding provides a novel mechanism of benefit for baricitinib and supports the safety profile of this immunomodulator for the treatment of coronavirus disease 2019. [ABSTRACT FROM AUTHOR] |
|
Copyright of Open Forum Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
